Piper Sandler analyst Peter Keith maintained a Buy rating on Boot Barn (BOOT – Research Report) today and set a price target of $179.00.

Piper Sandler analyst Anna Andreeva maintained a Hold rating on Steven Madden (SHOO – Research Report) today and set a price target of ...

President-elect Donald Trump has proposed stiff tariffs on imported goods, which could lead to higher prices and softer ...

The cost of clothing, for example ... a senior research analyst at Piper Sandler. The store, which sells discretionary items like toys and party hats, imports many of its items from China and ...

Piper Sandler has expressed optimism for the remainder of the year, particularly in corporate finance and advisory services. The company anticipates continued strength in the fourth quarter ...

NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Piper Sandler Companies (NYSE: PIPR), a leading investment bank, and BC Partners Credit, the $8 billion credit arm of international investment firm BC ...

On Monday, Piper Sandler showed a positive outlook for shares of USCB Financial Holdings (NASDAQ: USCB), shifting its rating from Neutral to Overweight and boosting the price target to $20.00 from ...

Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Derek Podhaizer as a director and senior research analyst to its energy equity research team.

Boston Beer (NYSE:SAM – Free Report) had its price objective boosted by Piper Sandler from $325.00 to $330.00 in a research note issued to investors on Friday morning, Benzinga reports.

Piper Sandler raised the firm’s price target on Mondelez (MDLZ) to $84 from $74 and keeps an Overweight rating on the shares. The firm notes Mondelez reported better than expected Q3 EPS and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering development of regulatory RNAs as a novel therapeutic ...